ArticleThe Journal of experimental medicine2018
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- Radiotherapy and DNA damage response inhibitors modestly sensitize HNSCC to NK cell killing, with ATM inhibition more effective than ATR inhibition.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- KMT9 drives T cell exclusion and dysfunction by promoting PMN-MDSCs infiltration and ARG1 expression in prostate cancer.Molecular cancer · 2026Article
- Review
- Impaired vitamin D signaling reveals neutrophils as key drivers of prostate cancer dissemination.EMBO molecular medicine · 2026Article
- HIF1 inhibition targets tumoral and myeloid cells, and is a promising therapy for metastatic castration-resistant prostate cancer.Cell death & disease · 2026Article
- Biomarkers for Recurrence and Prognosis in Metastatic Urothelial Cancer: Emerging Clinical Applications.Journal of Cancer · 2026Review
- Characterization of the immune landscape in healthy mouse prostate and during prostate cancer progression.Oncoimmunology · 2025Article
- Targeting immunosenesence promotes clearance of senescent cells.Immunity & ageing : I & A · 2025Review
- p53-loss induced prostatic epithelial cell plasticity and invasion is driven by a crosstalk with the tumor microenvironment.Cell death & disease · 2025Article
- Cellular senescence in metastatic prostate cancer: A therapeutic opportunity or challenge (Review).Molecular medicine reports · 2024Review
- Review
- NALCN-mediated sodium influx confers metastatic prostate cancer cell invasiveness.The EMBO journal · 2023Article
- Senescence of Tumor Cells in Anticancer Therapy-Beneficial and Detrimental Effects.International journal of molecular sciences · 2022Review
- Skin-Aging Pigmentation: Who Is the Real Enemy?Cells · 2022Review
- Hypoxia-mediated stabilization of HIF1A in prostatic intraepithelial neoplasia promotes cell plasticity and malignant progression.Science advances · 2022Article
- Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma.Cancer research · 2022Article
- Prostate luminal progenitor cells: from mouse to human, from health to disease.Nature reviews. Urology · 2022Review
- KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis.Molecular cancer · 2022Article
- Cellular senescence as a possible link between prostate diseases of the ageing male.Nature reviews. Urology · 2021Review
- Single-cell analyses unravel cell type-specific responses to a vitamin D analog in prostatic precancerous lesions.Science advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Maxime ParisottoDepartment of Functional Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Centre National de la Recherche Scientifique UMR7104/Institut National de la Santé et de la Recherche Médicale U1258, Université de Strasbourg, Illkirch Cedex, France.
Elise GreletDepartment of Functional Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Centre National de la Recherche Scientifique UMR7104/Institut National de la Santé et de la Recherche Médicale U1258, Université de Strasbourg, Illkirch Cedex, France.
Rana El BizriDepartment of Functional Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Centre National de la Recherche Scientifique UMR7104/Institut National de la Santé et de la Recherche Médicale U1258, Université de Strasbourg, Illkirch Cedex, France.
Yongyuan DaiDepartment of Functional Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Centre National de la Recherche Scientifique UMR7104/Institut National de la Santé et de la Recherche Médicale U1258, Université de Strasbourg, Illkirch Cedex, France.
Julie TerzicDepartment of Functional Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Centre National de la Recherche Scientifique UMR7104/Institut National de la Santé et de la Recherche Médicale U1258, Université de Strasbourg, Illkirch Cedex, France.
Doriane EckertDepartment of Functional Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Centre National de la Recherche Scientifique UMR7104/Institut National de la Santé et de la Recherche Médicale U1258, Université de Strasbourg, Illkirch Cedex, France.
Laetitia GargowitschDepartment of Functional Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Centre National de la Recherche Scientifique UMR7104/Institut National de la Santé et de la Recherche Médicale U1258, Université de Strasbourg, Illkirch Cedex, France.
Jean-Marc BornertDepartment of Functional Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Centre National de la Recherche Scientifique UMR7104/Institut National de la Santé et de la Recherche Médicale U1258, Université de Strasbourg, Illkirch Cedex, France.
Daniel MetzgerDepartment of Functional Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Centre National de la Recherche Scientifique UMR7104/Institut National de la Santé et de la Recherche Médicale U1258, Université de Strasbourg, Illkirch Cedex, France metzger@igbmc.fr.ORCID 0000-0002-5555-046X
Inserm · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic ablation of the tumor suppressor
Indexed as
Cellular SenescenceGene DeletionStress, PhysiologicalAnimalsBiomarkers, TumorCell ProliferationDNA DamageDNA RepairEpithelial CellsGene Expression Regulation, NeoplasticMaleMiceMyeloid CellsPhenotypeProstateProstatic NeoplasmsBiomarkers, TumorProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mdm2PTEN PhosphohydrolaseRNA, MessengerTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.